Business Context and Reporting Period
This Form 8-K was filed by Moderna, Inc. on October 16, 2023. The filing serves as a Regulation FD disclosure regarding the company's outlook for full-year 2023 revenues derived from its COVID-19 vaccine sales.
Key Financial Metrics
The filing does not report specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. It references a previously disclosed revenue guidance range for the full year 2023.
- Full Year 2023 COVID-19 Vaccine Revenue Guidance: $6 billion to $8 billion.
- Key Driver: U.S. vaccination rates and administered doses.
Material Changes and Outlook
Moderna reaffirmed its comfort with the $6 billion to $8 billion revenue guidance range established in its August 3, 2023, second-quarter earnings release. The company highlighted the following factors influencing the outcome:
- Lower End Scenario: If the U.S. market reaches approximately 50 million administered doses, revenues are expected to fall in the bottom half of the range.
- Upper End Scenario: If the U.S. market reaches approximately 100 million administered doses, revenues are expected to fall in the top half of the range.
- Visibility: Management stated it is too early in the U.S. vaccination season to accurately project final rates. Improved visibility is anticipated after reviewing trends through October 2023.
- Next Update: An update is scheduled for the earnings call on November 2, 2023.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Actual results may differ materially due to known and unknown risks, including uncertainties regarding U.S. vaccination rates and market size. The company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the actual U.S. administered dose counts for October 2023 to assess the likelihood of hitting the $6 billion vs. $8 billion revenue targets.
- Review the November 2, 2023, earnings call for updated guidance or revised revenue ranges.
- Monitor subsequent filings for any changes in the "Risk Factors" section related to vaccine demand or regulatory approvals.
